Background: The concepts of medication adherence and
Treatment satisfactions are commonly used in clinical research for assessing
pharmaceutical care and improving treatment outcomes. Generally, one would
expect a positive relationship between the two concepts. The objectives of this
study were to investigate the factors associated with adherence to
antihypertensive therapy among hypertensive patients and to assess the
relationship between antihypertensive medication adherence and treatment
satisfaction.
Methods: A cross-sectional study was conducted, adopting the Morisky eight-item
Medication Adherence Scale (MMAS) for the assessment of medication adherence
and using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4)
for the assessment of treatment satisfaction. Descriptive and comparative
statistics were used to describe socio-demographic and disease-related
characteristics of the patients. All analyses were performed using SPSS v 15.0.
Results: Four hundred and ten hypertensive patients were enrolled in the study.
The mean age of participants was 58.38 ± 10.65 years; 52% were female and
36.8% had low antihypertensive medication adherence. There was a significant
difference in the mean scores in the Effectiveness (p < 0.001), Convenience
(p < 0.001), and Global Satisfaction (p < 0.001) domains, but not in the
Side Effects (p = 0.466) domain among patients with different levels of
adherence. After adjustment for covariates using multiple linear regression,
global treatment satisfaction was still statistically significantly (p = 0.001)
associated with medication adherence.
Conclusions: Low treatment satisfaction may be an important barrier for
achieving high rates of adherence to treatment. These study findings could be
helpful in clinical practice, mainly in the early treatment of hypertensive
patients, at a point where improving treatment satisfaction is still possible.
To investigate differences in medication adherence, treatment satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic treatment regimens.
Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8) while treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were measured using the 24-item expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and analyzed using SPSS 16 for windows.
A convenience sample of 131 schizophrenic patients was studied. Patients belonged to 7 groups based on their antipsychotic treatment regimens. There was no significant difference in the means of adherence (P=0.6) and BPRS domains: positive (P=0.6), negative (P=0.8), manic (P=0.2) and depression (P=0.9) scores among the studied groups. Satisfaction with side effect domain was significantly different among studied groups (P=0.006, F=3). However, no significant difference was found in other satisfaction domains: effectiveness (P=0.8), convenience (P=0.3), and global satisfaction (P=0.8).
Medications adherence, most treatment satisfaction domains and clinical symptom scores were not significantly different among patients taking different antipsychotic regimens.
In Arab and Muslim-dominated countries, spirituality and religiosity shape the belief and practices toward chronic illnesses. No previous studies were published to assess adherence to and satisfaction with antipsychotic medications in persons with schizophrenia in the Arab world. Objective: To assess medication adherence and treatment satisfaction with antipsychotics in a sample of Palestinian people with schizophrenia. Methodology: Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for windows. Results: A convenience sample of 131 persons with schizophrenia was studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly correlated (P=0.028) with adherence score. However, variables like use of monotherapy or atypical or depot antipsychotics were not significantly associated with higher adherence. The means of satisfaction with regard to effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5, 67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant difference in the means of effectiveness (P<0.01), convenience (P<0.01), global satisfaction (P<0.01), but not side effects domains (P=0.1) among persons with different levels of adherence. Furthermore, there was a significant difference in the means of positive symptom score (P<0.01), manic (P<0.01) and depression (P<0.01) but not negative symptom score (P=0.4) among persons with different levels of adherence. Conclusions: Medication nonadherence was common and was associated with low treatment satisfaction scores and poor psychiatric scores. Medication related factors had insignificant effects on adherence scores.
Background: In Arab and Muslim-dominated countries, spirituality and religiosity shape the belief and practices toward chronic illnesses. No previous studies were published to assess adherence to and satisfaction with antipsychotic medications in persons with schizophrenia in the Arab world. Objective: To assess medication adherence and treatment satisfaction with antipsychotics in a sample of Palestinian people with schizophrenia. Methodology: Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for windows. Results: A convenience sample of 131 persons with schizophrenia was studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly correlated (P=0.028) with adherence score. However, variables like use of monotherapy or atypical or depot antipsychotics were not significantly associated with higher adherence. The means of satisfaction with regard to effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5, 67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant difference in the means of effectiveness (P < 0.01), convenience (P < 0.01), global satisfaction (P < 0.01), but not side effects domains (P=0.1) among persons with different levels of adherence. Furthermore, there was a significant difference in the means of positive symptom score (P < 0.01), manic (P < 0.01) and depression (P < 0.01) but not negative symptom score (P=0.4) among persons with different levels of adherence. Conclusions: Medication nonadherence was common and was associated with low treatment satisfaction scores and poor psychiatric scores. Medication related factors had insignificant effects on adherence scores
In Arab and Muslim-dominated countries, spirituality and religiosity shape the belief and practices toward chronic illnesses. No previous studies were published to assess adherence to and satisfaction with antipsychotic medications in persons with schizophrenia in the Arab world. Objective: To assess medication adherence and treatment satisfaction with antipsychotics in a sample of Palestinian people with schizophrenia. Methodology: Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for windows. Results: A convenience sample of 131 persons with schizophrenia was studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly correlated (P=0.028) with adherence score. However, variables like use of monotherapy or atypical or depot antipsychotics were not significantly associated with higher adherence. The means of satisfaction with regard to effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5, 67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant difference in the means of effectiveness (P<0.01), convenience (P<0.01), global satisfaction (P<0.01), but not side effects domains (P=0.1) among persons with different levels of adherence. Furthermore, there was a significant difference in the means of positive symptom score (P<0.01), manic (P<0.01) and depression (P<0.01) but not negative symptom score (P=0.4) among persons with different levels of adherence. Conclusions: Medication nonadherence was common and was associated with low treatment satisfaction scores and poor psychiatric scores. Medication related factors had insignificant effects on adherence scores.
In Arab and Muslim-dominated countries, spirituality and religiosity shape the belief and practices toward chronic illnesses. No previous studies were published to assess adherence to and satisfaction with antipsychotic medications in persons with schizophrenia in the Arab world. Objective: To assess medication adherence and treatment satisfaction with antipsychotics in a sample of Palestinian people with schizophrenia. Methodology: Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for windows. Results: A convenience sample of 131 persons with schizophrenia was studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly correlated (P=0.028) with adherence score. However, variables like use of monotherapy or atypical or depot antipsychotics were not significantly associated with higher adherence. The means of satisfaction with regard to effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5, 67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant difference in the means of effectiveness (P<0.01), convenience (P<0.01), global satisfaction (P<0.01), but not side effects domains (P=0.1) among persons with different levels of adherence. Furthermore, there was a significant difference in the means of positive symptom score (P<0.01), manic (P<0.01) and depression (P<0.01) but not negative symptom score (P=0.4) among persons with different levels of adherence. Conclusions: Medication nonadherence was common and was associated with low treatment satisfaction scores and poor psychiatric scores. Medication related factors had insignificant effects on adherence scores.
Background: In Arab and Muslim-dominated countries,
spirituality and religiosity shape the belief and practices toward chronic
illnesses. No previous studies were published to assess adherence to and
satisfaction with antipsychotic medications in persons with schizophrenia in
the Arab world.
Objective: To assess medication adherence and treatment
satisfaction with antipsychotics in a sample of Palestinian people with
schizophrenia. Methodology: Medication adherence was assessed using the 8-item
Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed
using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4).
Psychiatric symptoms were assessed using the expanded Brief Psychiatric Rating
Scale (BPRS-E). Data were entered and statistically analyzed using SPSS 16 for
windows. Results: A convenience sample of 131 persons with schizophrenia was
studied. Based on MMAS-8, 44 persons (33.6%) had a low rate, 58 (44.3%) had a
medium rate and 29 (22.1%) had a high rate of adherence. Age was significantly
correlated (P=0.028) with adherence score. However, variables like use of
monotherapy or atypical or depot antipsychotics were not significantly
associated with higher adherence. The means of satisfaction with regard to
effectiveness, side effects, convenience and global satisfaction were 72.6 ± 20.5,
67.9 ± 31.47, 63.2 ± 14.3 and 63.1 ± 18.8 respectively. There was a significant
difference in the means of effectiveness (P < 0.01), convenience (P <
0.01), global satisfaction (P < 0.01), but not side effects domains (P=0.1)
among persons with different levels of adherence. Furthermore, there was a
significant difference in the means of positive symptom score (P < 0.01),
manic (P < 0.01) and depression (P < 0.01) but not negative symptom score
(P=0.4) among persons with different levels of adherence.
Conclusions:
Medication nonadherence was common and was associated with low treatment
satisfaction scores and poor psychiatric scores. Medication related factors had
insignificant effects on adherence scores